The Future of Omics 2025
Location: Shenzhen, China
Dates: September 9–10, 2025
September 9
International Conference Centre, Function Hall 1
Morning 9:00 - 12:30 - BGI Group Product Launch
Afternoon 14:00 - 16:30 - BGI Centre Tour
Evening 18:00 - 20:30 - VIP Networking Dinner (by invitation only)
September 10
Meeting Room, Level 10
9:00 – 9:10 Opening Speech
Keynote Presentations
- 9:10 – 9:40
DNBseq – 10 Years and Beyond
Jian Liu, Executive Vice President, MGI - 9:40 – 10:10
AI Transforms Life Sciences: BGI's Journey from 'Decoding' to 'Designing'
Meng Yang, Senior Vice President, MGI - 10:10 – 10:40
Pushing Spatial Omics to New Frontiers: Stereo-seq at Nanoscale Resolution
Ao Chen, Chief Scientist, STOmics
Tea Break & Networking
10:40 – 11:00
10:40 – 11:00
- 11:00 – 11:25
The Chinese Pangenome Reference Phase II: Building Natural Population Baselines and Advancing Medical Genetics
Shuhua Xu, Professor, Fudan University - 11:25 – 11:50
Single-cell Spatial Transcriptome Atlas and Whole-Brain Connectivity of the Macaque Claustrum
Zhiming Shen, Principal Investigator, CEBSIT, CAS - 11:50 – 12:15
RNA Multi-Omics: Single-Cell, Spatiotemporal, and Direct Sequencing by CYCLONE-seq
Liang Chen, Principal Scientist, BGI Research–Wuhan
Lunch & Networking
12:15 – 13:45
12:15 – 13:45
Afternoon — Forums
Product Launch
- 13:45 – 14:15
GLI New Product Launch
Tiancheng "Curly" Zuo, Product Manager, GLI, MGI - 14:15 – 14:35
Bioinformatic Solutions Empower the Expansion of Multi-Omics Applications
Yao Xiao, MGI
SEQALL User Experience Sharing
- 14:35 – 14:50
Whole genome sequencing of 500,000 Chinese in CKB: initial findings
Xin Jin, Director, Institute of Precision Health, BGI Research - 14:50 – 15:05
Transforming Cancer Care through Whole Genome Sequencing, Data, and AI
Justin Lee, CEO, Inocras KR - 15:05 – 15:20
High-Resolution Variant Profiling for Monogenic Disorders by Long-read sequencing
Jiale Xiang, BGI Research - 15:20 – 15:35
An integrated toolkit advancing Cyclone performance for genome research
Chentao Yang, Deputy Director, Institute for Digitization of Earth Life, BGI Research
Tea Break & Networking
15:35 – 15:55
15:35 – 15:55
Products & Application Advances
- 15:55 – 16:10
Accelerating SNP Screening Through MGI ATOPlex and Low-pass Whole-Genome Sequencing Technology
Feng Liu, Assistant Researcher, MGI - 16:10 – 16:25
BGI GenSIRO – All-in-one Localization (Turnkey) Solution
Amy Ho Mei Ying, Senior Automation Application Engineer, BGI Genomics - 16:25 – 16:40
Precision with a Purpose: Benchmark 659 CGP Assay for Cancer Care – Powered by MGI
Boris Wong, Senior Molecular and Bioinformatics Scientist, LifeStrands Genomics (Australia) - 16:40 – 16:55
Turnkey Spatial Proteomics: End-to-End mIF platform with DNBSEQ-G400 FluoXpert
Jack Wang, Project Lead, FluoXpert project, MGI Tech - 16:55 – 17:10
Functional and Multi-omic Counteraction of Aging with GLP-1R Agonism
Dr. Andrew Kwok, CUHK
Emerging Frontier Technologies
- 17:10 – 17:30
Stereo-cell: Spatial Enhanced Resolution Single-Cell Sequencing with High-Density DNA Nanoball-Patterned Arrays
Chang Liu, Associate Researcher, BGI Research - 17:30 – 17:50
Joint Analysis of Single-Cell and Spatial Omics Datasets
Yong Zhang, Principal Scientist, BGI Research–Wuhan
Close
FO2025 Speakers
Jian Liu
Executive Vice President of MGI
Talk Title: “10 Years of DNBSEQ: A Decade Shared, A Future Forged”
Abstract: Marking the 10th anniversary of DNBSEQ, this speech reflects on a decade of innovation and growth. It highlights DNBSEQ’s competitive advantages in the current MPS market and its open, collaborative ecosystem. Looking ahead, it outlines future goals—including technical advancements and expanded applications—alongside a broader vision: to scale DNBSEQ’s global impact, empower life sciences, and drive innovation across diverse fields.
Bio: Liu Jian is Executive Vice President of MGI and Head of MGI Americas. He led the development of China’s first mass-produced clinical sequencer, the BGISEQ-500, and the DNBSEQ platform, giving MGI independent control of core sequencing technologies and driving rapid improvements in throughput, turnaround time, and cost. A holder of dozens of patents and national honors, he has overseen global delivery of more than five thousand sequencers and coordinated pandemic-response deployments across over one hundred countries. Since 2021, Jian has built MGI’s Americas commercial and manufacturing presence, establishing a San Jose facility and successfully relaunching DNBSEQ in the U.S. market.
Abstract: Marking the 10th anniversary of DNBSEQ, this speech reflects on a decade of innovation and growth. It highlights DNBSEQ’s competitive advantages in the current MPS market and its open, collaborative ecosystem. Looking ahead, it outlines future goals—including technical advancements and expanded applications—alongside a broader vision: to scale DNBSEQ’s global impact, empower life sciences, and drive innovation across diverse fields.
Bio: Liu Jian is Executive Vice President of MGI and Head of MGI Americas. He led the development of China’s first mass-produced clinical sequencer, the BGISEQ-500, and the DNBSEQ platform, giving MGI independent control of core sequencing technologies and driving rapid improvements in throughput, turnaround time, and cost. A holder of dozens of patents and national honors, he has overseen global delivery of more than five thousand sequencers and coordinated pandemic-response deployments across over one hundred countries. Since 2021, Jian has built MGI’s Americas commercial and manufacturing presence, establishing a San Jose facility and successfully relaunching DNBSEQ in the U.S. market.
Dr. Ao Chen
Chief Scientist – STOmics
Talk Title: “Pushing Spatial Omics to New Frontiers: Stereo-seq at Nanoscale Resolution”
Abstract: Stereo-seq combines 500 nm spatial resolution with a >160 cm² field of view, enabling high-throughput spatial multi-omics on fresh frozen and FFPE tissues. Applications include spatiotemporal atlas construction, evolutionary studies, disease pathology, and therapeutic development, demonstrating the technology’s transformative impact on spatial biology.
Bio: Dr. Ao Chen is a pioneer in spatial omics and sequencing technologies, co-developing the high-resolution Stereo-seq platform that achieves nanoscale spatial transcriptomics across large tissue areas. His technological innovations enable detailed mapping of cellular and molecular landscapes in biological systems, applicable to development, neuroscience, and cancer. Chen has numerous patents and publications documenting the platform’s ability to reveal complex tissue architectures and cellular interactions at unprecedented resolution, driving next-generation precision medicine and biological research.
Abstract: Stereo-seq combines 500 nm spatial resolution with a >160 cm² field of view, enabling high-throughput spatial multi-omics on fresh frozen and FFPE tissues. Applications include spatiotemporal atlas construction, evolutionary studies, disease pathology, and therapeutic development, demonstrating the technology’s transformative impact on spatial biology.
Bio: Dr. Ao Chen is a pioneer in spatial omics and sequencing technologies, co-developing the high-resolution Stereo-seq platform that achieves nanoscale spatial transcriptomics across large tissue areas. His technological innovations enable detailed mapping of cellular and molecular landscapes in biological systems, applicable to development, neuroscience, and cancer. Chen has numerous patents and publications documenting the platform’s ability to reveal complex tissue architectures and cellular interactions at unprecedented resolution, driving next-generation precision medicine and biological research.
Dr. Liang Chen
Principal Scientist – BGI Research Wuhan
Talk Title: “RNA Multi-Omics: Single-Cell, Spatiotemporal, and Direct Sequencing by CYCLONE-seq”
Abstract: scCYCLONE-seq is a next-generation single-cell long-read sequencing platform integrating DNBelab C microfluidics with CycloneSEQ nanopore chemistry for full-length isoform and splicing analysis. Applied to early zebrafish embryos, it revealed extensive isoform diversity and regulatory dynamics, and is expanding to spatiotemporal and direct RNA sequencing to decode the “Splicing–Modification Code.”
Bio: Dr. Liang Chen is Principal Scientist and head of the Cell-Omics Technology R&D Center at BGI-Research Wuhan, and adjunct professor at the Hangzhou Institute for Advanced Study. He develops advanced single-cell and spatial omics technologies to study gene regulation in development and cancer. His work includes pioneering sequencing methods, constructing the first spatial transcriptome atlas for axolotl brain regeneration, and revealing molecular mechanisms of tissue repair. Author of around fifty publications in leading journals, Dr. Chen has led major research projects, trained young scientists, and continues advancing RNA multi-omics to decode regulatory networks controlling cell fate and function.
Abstract: scCYCLONE-seq is a next-generation single-cell long-read sequencing platform integrating DNBelab C microfluidics with CycloneSEQ nanopore chemistry for full-length isoform and splicing analysis. Applied to early zebrafish embryos, it revealed extensive isoform diversity and regulatory dynamics, and is expanding to spatiotemporal and direct RNA sequencing to decode the “Splicing–Modification Code.”
Bio: Dr. Liang Chen is Principal Scientist and head of the Cell-Omics Technology R&D Center at BGI-Research Wuhan, and adjunct professor at the Hangzhou Institute for Advanced Study. He develops advanced single-cell and spatial omics technologies to study gene regulation in development and cancer. His work includes pioneering sequencing methods, constructing the first spatial transcriptome atlas for axolotl brain regeneration, and revealing molecular mechanisms of tissue repair. Author of around fifty publications in leading journals, Dr. Chen has led major research projects, trained young scientists, and continues advancing RNA multi-omics to decode regulatory networks controlling cell fate and function.
Amy Ho Mei Ying
Senior Automation Application Engineer – BGI Health, Hong Kong
Talk Title: “BGI GenSIRO—All-in-One Localization (Turnkey) Solution”
Abstract: Introduction to the GenSIRO AI+ platform for localized NGS testing, featuring a “sample in, report out” visual interface, solution portfolio, application case studies, and performance data to showcase its advantages in automated, integrated genomic workflows.
Bio: Amy Ho specializes in the development and implementation of automation solutions for genomic laboratories, leading projects that integrate robotics and advanced instrumentation such as Hamilton, Tecan, and MGI platforms. She ensures high-throughput, reproducible workflows suitable for clinical and research applications. Amy played a vital role in deploying automation during the COVID-19 pandemic for large-scale molecular testing and drives innovation in turnkey automation pipelines, facilitating efficient sample processing and data generation. Her work supports scalable genomic diagnostics through automated laboratory workflows.
Abstract: Introduction to the GenSIRO AI+ platform for localized NGS testing, featuring a “sample in, report out” visual interface, solution portfolio, application case studies, and performance data to showcase its advantages in automated, integrated genomic workflows.
Bio: Amy Ho specializes in the development and implementation of automation solutions for genomic laboratories, leading projects that integrate robotics and advanced instrumentation such as Hamilton, Tecan, and MGI platforms. She ensures high-throughput, reproducible workflows suitable for clinical and research applications. Amy played a vital role in deploying automation during the COVID-19 pandemic for large-scale molecular testing and drives innovation in turnkey automation pipelines, facilitating efficient sample processing and data generation. Her work supports scalable genomic diagnostics through automated laboratory workflows.
Dr. Xin Jin
Director, Institute of Precision Health – BGI Research
Talk Title: “Whole Genome Sequencing of 500,000 Chinese in CKB: Initial Findings”
Abstract: Analysis of ~500,000 China Kadoorie Biobank WGS data reveals 457.7 million genetic variants (230.2 million novel), population structure gradients, Neanderthal and Denisovan introgressions, regional pharmacogenomic disparities, and 64,658 high-confidence structural variations, alongside a comprehensive microbial genome catalog and Microbe-Disease association atlas to advance precision medicine.
Bio: Leading efforts in large-scale genomic projects, Dr. Xin Jin focuses on population genomics and precision medicine. His work includes contributions to the 1000 Genomes Project and disease-focused studies like Sino-Danish Diabetes and Autism Genome projects. Currently, he heads research on whole-genome sequencing in the China Kadoorie Biobank (CKB), analyzing genomic variants from 500,000 Chinese individuals to understand genetic diversity and disease susceptibility. His team discovered novel genetic variants, patterns of population structure, and interplays involving environmental factors and microbiomes. With numerous high-impact publications in journals such as Cell and Nature, Dr. Jin advances big-data driven applications to enhance clinical diagnostics using cell-free nucleic acids and deepen insights into human health and disease.
Abstract: Analysis of ~500,000 China Kadoorie Biobank WGS data reveals 457.7 million genetic variants (230.2 million novel), population structure gradients, Neanderthal and Denisovan introgressions, regional pharmacogenomic disparities, and 64,658 high-confidence structural variations, alongside a comprehensive microbial genome catalog and Microbe-Disease association atlas to advance precision medicine.
Bio: Leading efforts in large-scale genomic projects, Dr. Xin Jin focuses on population genomics and precision medicine. His work includes contributions to the 1000 Genomes Project and disease-focused studies like Sino-Danish Diabetes and Autism Genome projects. Currently, he heads research on whole-genome sequencing in the China Kadoorie Biobank (CKB), analyzing genomic variants from 500,000 Chinese individuals to understand genetic diversity and disease susceptibility. His team discovered novel genetic variants, patterns of population structure, and interplays involving environmental factors and microbiomes. With numerous high-impact publications in journals such as Cell and Nature, Dr. Jin advances big-data driven applications to enhance clinical diagnostics using cell-free nucleic acids and deepen insights into human health and disease.
Dr. Andrew Kwok
Clinician-scientist, Department of Medicine and Therapeutics, CUHK
Talk Title: “Functional and Multi-omic Counteraction of Aging with GLP-1R Agonism”
Abstract: Identifying effective interventions against aging is vital for addressing age-related disorders. In aging male mice treated with a GLP-1 receptor agonist (GLP-1RA) for 13–30 weeks, we observed improved physical performance and strong age-counteracting effects across transcriptomes, methylomes, metabolomes, and immune profiles. These benefits were specific to older animals, achieved at low dosage, and largely dependent on hypothalamic GLP-1R, pointing to a brain–body axis in aging. Benchmarking against mTOR inhibition revealed close parallels. These findings illuminate the pleiotropic effects of GLP-1RAs and inform design of anti-aging therapeutics and clinical trials.
Bio: Dr. Andrew John Kwok is a clinician-scientist at CUHK specializing in neuroimmunology, neurodegeneration, and single-cell genomics. He integrates multi-omic technologies with machine learning to investigate how gene expression and epigenetic states direct cellular function. Kwok has published on immune responses, aging biology, and neurological disease, and contributed open-source bioinformatics tools for both general and disease-specific applications. His current research centers on GLP-1 receptor agonism as a means to counteract molecular and physiological aging through brain–body signaling. He also studies neuroinflammation and T cell–mediated neurological disorders, with a focus on translating mechanistic insights into clinical interventions to improve patient outcomes worldwide.
Abstract: Identifying effective interventions against aging is vital for addressing age-related disorders. In aging male mice treated with a GLP-1 receptor agonist (GLP-1RA) for 13–30 weeks, we observed improved physical performance and strong age-counteracting effects across transcriptomes, methylomes, metabolomes, and immune profiles. These benefits were specific to older animals, achieved at low dosage, and largely dependent on hypothalamic GLP-1R, pointing to a brain–body axis in aging. Benchmarking against mTOR inhibition revealed close parallels. These findings illuminate the pleiotropic effects of GLP-1RAs and inform design of anti-aging therapeutics and clinical trials.
Bio: Dr. Andrew John Kwok is a clinician-scientist at CUHK specializing in neuroimmunology, neurodegeneration, and single-cell genomics. He integrates multi-omic technologies with machine learning to investigate how gene expression and epigenetic states direct cellular function. Kwok has published on immune responses, aging biology, and neurological disease, and contributed open-source bioinformatics tools for both general and disease-specific applications. His current research centers on GLP-1 receptor agonism as a means to counteract molecular and physiological aging through brain–body signaling. He also studies neuroinflammation and T cell–mediated neurological disorders, with a focus on translating mechanistic insights into clinical interventions to improve patient outcomes worldwide.
Justin Lee
Co-founder and Chief Innovation Officer, INOCRAS
Talk Title: “Transforming Cancer Care through Whole Genome Sequencing, Data, and AI”
Abstract: Whole genome sequencing (WGS) is transforming oncology by enabling comprehensive genomic profiling and ultra-sensitive minimal residual disease (MRD) detection. Inocras has developed a proprietary Target-Enhanced WGS (CancerVision™) that integrates somatic and germline testing with high accuracy, rapid turnaround, and clinical-grade bioinformatics. Compared with conventional targeted panels, CancerVision provides broader variant detection, robust HRD, MSI, and mutational signature analyses, and demonstrated clinical validity in prospective hospital studies. Complementing this, MRDVision™ leverages whole-genome–to–whole-genome tracking to achieve unprecedented sensitivity, with limits of detection down to 1 part per million, matching or surpassing panel-based assays. Together, these approaches redefine precision oncology by bridging comprehensive profiling and real-time disease monitoring, offering a scalable framework for clinical diagnostics and pharmaceutical applications.
Bio: Jeong Seok co-founded Inocras and paved a way to productize innovation in genomic technology into diagnostic products. He currently serves as Chief Innovation Officer, leading partnership for external innovation and Korean business as a General Manager at Inocras Korea. He established a foundation for providing Inocras’s multi-omics technology to various companies and institutions (Sci Immunol 2020, Nat Comm 2021). Under his leadership, Inocras successfully developed CancerVision™ and MRDVision™ platforms. He is a physician scientist and healthcare innovator experienced in internal medicine, rheumatology, and immunology. He received his MD at Seoul National University and his Ph.D. in Human Immunology at KAIST.
Abstract: Whole genome sequencing (WGS) is transforming oncology by enabling comprehensive genomic profiling and ultra-sensitive minimal residual disease (MRD) detection. Inocras has developed a proprietary Target-Enhanced WGS (CancerVision™) that integrates somatic and germline testing with high accuracy, rapid turnaround, and clinical-grade bioinformatics. Compared with conventional targeted panels, CancerVision provides broader variant detection, robust HRD, MSI, and mutational signature analyses, and demonstrated clinical validity in prospective hospital studies. Complementing this, MRDVision™ leverages whole-genome–to–whole-genome tracking to achieve unprecedented sensitivity, with limits of detection down to 1 part per million, matching or surpassing panel-based assays. Together, these approaches redefine precision oncology by bridging comprehensive profiling and real-time disease monitoring, offering a scalable framework for clinical diagnostics and pharmaceutical applications.
Bio: Jeong Seok co-founded Inocras and paved a way to productize innovation in genomic technology into diagnostic products. He currently serves as Chief Innovation Officer, leading partnership for external innovation and Korean business as a General Manager at Inocras Korea. He established a foundation for providing Inocras’s multi-omics technology to various companies and institutions (Sci Immunol 2020, Nat Comm 2021). Under his leadership, Inocras successfully developed CancerVision™ and MRDVision™ platforms. He is a physician scientist and healthcare innovator experienced in internal medicine, rheumatology, and immunology. He received his MD at Seoul National University and his Ph.D. in Human Immunology at KAIST.
Chang Liu
Associate Researcher – BGI Life Sciences Institute
Talk Title: “Stereo-cell: Spatial Enhanced Resolution Single-Cell Sequencing with High-Density DNA Nanoball-Patterned Arrays”
Abstract: A spatially resolved, high-throughput single-cell transcriptomic platform built on high-density DNA nanoball patterned arrays, enabling scalable capture of 200–1 million cells per chip, deep learning–based cell segmentation, rare immune cell detection, subcellular transcript localization, and concurrent mRNA/protein multi-modal profiling across diverse sample types.
Bio: Chang Liu’s research centers on the development of spatially resolved single-cell transcriptomics using novel technologies such as Stereo-cell, which utilizes high-density DNA nanoball patterned arrays. These methods overcome limitations of conventional single-cell approaches, enabling unbiased, high-throughput capture of cellular transcriptomes across diverse sample types and sizes. His work includes mapping immune cell heterogeneity, resolving subcellular transcript localization, and integrating multi-modal data including protein markers. Liu’s research significantly enhances the understanding of tissue microenvironments and cellular interactions, supporting breakthroughs in developmental biology and disease research through innovative spatial multi-omics tools.
Abstract: A spatially resolved, high-throughput single-cell transcriptomic platform built on high-density DNA nanoball patterned arrays, enabling scalable capture of 200–1 million cells per chip, deep learning–based cell segmentation, rare immune cell detection, subcellular transcript localization, and concurrent mRNA/protein multi-modal profiling across diverse sample types.
Bio: Chang Liu’s research centers on the development of spatially resolved single-cell transcriptomics using novel technologies such as Stereo-cell, which utilizes high-density DNA nanoball patterned arrays. These methods overcome limitations of conventional single-cell approaches, enabling unbiased, high-throughput capture of cellular transcriptomes across diverse sample types and sizes. His work includes mapping immune cell heterogeneity, resolving subcellular transcript localization, and integrating multi-modal data including protein markers. Liu’s research significantly enhances the understanding of tissue microenvironments and cellular interactions, supporting breakthroughs in developmental biology and disease research through innovative spatial multi-omics tools.
Feng Liu
BioTech Assistant Researcher, Multi-omics R&D Centre, MGI Tech
Talk Title: “Accelerating SNP Screening Through MGI ATOPlex and Lowpass Whole-Genome Sequencing Technology”
Abstract: Introduction to MGI’s ATOPlex targeted NGS platform and Lowpass WGS solution, demonstrating streamlined workflows and applications for rapid SNP screening in research and clinical contexts.
Bio: Feng Liu earned his master’s degree at Southern University of Science and Technology before joining MGI Tech in 2022. Based in the Multi-omics R&D Center, he leads the development of the Lowpass whole-genome sequencing (WGS) product suite and drives optimization of the MGI ATOPlex targeted NGS platform. His work integrates novel assay design with automated library preparation to accelerate SNP screening workflows. Feng collaborates closely with cross-functional teams to refine chemistry and informatics, ensuring robust performance across diverse sample types. His contributions have advanced MGI’s ATOPlex and Lowpass WGS solutions toward broad adoption in research and clinical genomics.
Abstract: Introduction to MGI’s ATOPlex targeted NGS platform and Lowpass WGS solution, demonstrating streamlined workflows and applications for rapid SNP screening in research and clinical contexts.
Bio: Feng Liu earned his master’s degree at Southern University of Science and Technology before joining MGI Tech in 2022. Based in the Multi-omics R&D Center, he leads the development of the Lowpass whole-genome sequencing (WGS) product suite and drives optimization of the MGI ATOPlex targeted NGS platform. His work integrates novel assay design with automated library preparation to accelerate SNP screening workflows. Feng collaborates closely with cross-functional teams to refine chemistry and informatics, ensuring robust performance across diverse sample types. His contributions have advanced MGI’s ATOPlex and Lowpass WGS solutions toward broad adoption in research and clinical genomics.
Dr. Zhiming Shen
Principle Investigator – Center for Excellence in Brain Science and Intelligence Technology, CAS
Talk Title: “Single-Cell Spatial Transcriptome Atlas and Whole-Brain Connectivity of the Macaque Claustrum”
Abstract: Single-nucleus RNA sequencing of 227,750 macaque claustral cells identified 48 transcriptome-defined cell types, with comparison across species revealing macaque-specific types. Retrograde tracer injections at 67 cortical and 7 subcortical regions delineated four distinct connectivity zones. Integrating spatial transcriptomics with connectivity data uncovered preferential glutamatergic projections to entorhinal cortex/hippocampus versus motor cortex/putamen, providing a high-resolution atlas of claustrum organization and function.
Bio: Dr. Zhiming Shen is a neuroscientist focusing on mesoscale brain mapping in primates. His research integrates single-nucleus RNA sequencing and anatomical tracing to elucidate the cellular and molecular organization of the macaque brain claustrum. Shen’s group identified distinct neuronal types and connectivity zones, revealing species-specific features and functional networks. His work advances understanding of brain circuits underlying complex functions by building high-resolution molecular and connectivity atlases. Shen has contributed significantly to primate neuroscience with publications in top journals including Cell and Science.
Abstract: Single-nucleus RNA sequencing of 227,750 macaque claustral cells identified 48 transcriptome-defined cell types, with comparison across species revealing macaque-specific types. Retrograde tracer injections at 67 cortical and 7 subcortical regions delineated four distinct connectivity zones. Integrating spatial transcriptomics with connectivity data uncovered preferential glutamatergic projections to entorhinal cortex/hippocampus versus motor cortex/putamen, providing a high-resolution atlas of claustrum organization and function.
Bio: Dr. Zhiming Shen is a neuroscientist focusing on mesoscale brain mapping in primates. His research integrates single-nucleus RNA sequencing and anatomical tracing to elucidate the cellular and molecular organization of the macaque brain claustrum. Shen’s group identified distinct neuronal types and connectivity zones, revealing species-specific features and functional networks. His work advances understanding of brain circuits underlying complex functions by building high-resolution molecular and connectivity atlases. Shen has contributed significantly to primate neuroscience with publications in top journals including Cell and Science.
Dr. Boris Wong
Senior Molecular and Bioinformatics Scientist - MLabMed
Talk Title: “Precision with a Purpose: Benchmark 659 CGP Assay for Cancer Care – Powered by MGI”
Abstract: OncoStrands Benchmark 659 CGP assay screens 650 DNA and 110 RNA genes for small variants, CNVs (including BRCA1/2 exon-level), chromosome arm–level gains and losses, known and novel fusions, splice variants, TMB, MSI, and mutational signatures using MGISP-Smart 8 and DNBSEQ-G400, delivering high-quality data and actionable insights in a 14-day turnaround.
Bio: Boris Wong is a Senior Molecular and Bioinformatics Scientist with a BSc in Biomedical Science from The University of Adelaide and an MLabMed from RMIT University. After working at Roche Diagnostics and Siemens Healthineers, he joined the Myeloma Research Group at the Australian Centre for Blood Diseases. In 2018, he began his PhD at La Trobe University and the Olivia Newton-John Cancer Research Institute, developing bioinformatic pipelines for personalized biomarkers and liquid biopsy monitoring. He also oversaw ISO 15189 molecular diagnostics at The University of Melbourne’s Department of Surgery. Since 2022, he has led CGP assay development at LifeStrands.
Abstract: OncoStrands Benchmark 659 CGP assay screens 650 DNA and 110 RNA genes for small variants, CNVs (including BRCA1/2 exon-level), chromosome arm–level gains and losses, known and novel fusions, splice variants, TMB, MSI, and mutational signatures using MGISP-Smart 8 and DNBSEQ-G400, delivering high-quality data and actionable insights in a 14-day turnaround.
Bio: Boris Wong is a Senior Molecular and Bioinformatics Scientist with a BSc in Biomedical Science from The University of Adelaide and an MLabMed from RMIT University. After working at Roche Diagnostics and Siemens Healthineers, he joined the Myeloma Research Group at the Australian Centre for Blood Diseases. In 2018, he began his PhD at La Trobe University and the Olivia Newton-John Cancer Research Institute, developing bioinformatic pipelines for personalized biomarkers and liquid biopsy monitoring. He also oversaw ISO 15189 molecular diagnostics at The University of Melbourne’s Department of Surgery. Since 2022, he has led CGP assay development at LifeStrands.
Dr. Jiale Xiang
PhD, R&D Director – BGI Genomics
Talk Title: “High-Resolution Variant Profiling for Monogenic Disorders by Long-Read Sequencing”
Abstract: High-throughput sequencing (also known as short-read sequencing) has been widely applied in the clinical screening and diagnosis of genetic disorders. However, due to its inherent read length limitations, this technology shows constraints in detecting complex structural variants, pseudogenes, and high-GC regions. In contrast, long-read sequencing, with its extended read length, enables more accurate characterization of such complex variants. In this study, we systematically investigated the application of long-read sequencing in clinical settings, providing robust data support and scientific evidence for its adoption as a precise diagnostic tool in genomic medicine.
Bio: Dr. Jiale Xiang leads research on genomic technologies for clinical diagnostics, specializing in the application of long-read sequencing for rare and complex genetic disorders. His work addresses the limitations of short-read sequencing by enabling accurate detection of structural variants, repetitive regions, and pseudogenes, critical for monogenic disease diagnostics. He has contributed to national standards and holds numerous patents in sequencing technology. Dr. Xiang’s research supports the clinical integration of advanced genomic platforms, enhancing diagnostic precision and providing robust evidence for precision medicine implementations.
Abstract: High-throughput sequencing (also known as short-read sequencing) has been widely applied in the clinical screening and diagnosis of genetic disorders. However, due to its inherent read length limitations, this technology shows constraints in detecting complex structural variants, pseudogenes, and high-GC regions. In contrast, long-read sequencing, with its extended read length, enables more accurate characterization of such complex variants. In this study, we systematically investigated the application of long-read sequencing in clinical settings, providing robust data support and scientific evidence for its adoption as a precise diagnostic tool in genomic medicine.
Bio: Dr. Jiale Xiang leads research on genomic technologies for clinical diagnostics, specializing in the application of long-read sequencing for rare and complex genetic disorders. His work addresses the limitations of short-read sequencing by enabling accurate detection of structural variants, repetitive regions, and pseudogenes, critical for monogenic disease diagnostics. He has contributed to national standards and holds numerous patents in sequencing technology. Dr. Xiang’s research supports the clinical integration of advanced genomic platforms, enhancing diagnostic precision and providing robust evidence for precision medicine implementations.
Dr. Yao Xiao
Bioinformatics Product Manager & GLI R&D, MGI Tech
Talk Title: “Bioinformatic Solutions Empower the Expansion of Multi-Omics Applications”
Abstract: Presentation of a bioinformatics product matrix, case studies in emerging application areas, and strategies for extending multi-omics workflows across diverse research scenarios.
Bio: Dr. Yao Xiao obtained her PhD from the Hong Kong University of Science and Technology, where she applied bioinformatics tools to marine ecology studies, publishing over ten SCI-indexed papers. In early 2025, she joined MGI Tech as a Bioinformatics Product Manager and has since contributed to the development of Generative Lab Intelligence (GLI) automation solutions. Yao oversees the design and implementation of a comprehensive bioinformatics product matrix, enabling seamless integration of data processing pipelines across multi-omics applications. Her expertise spans algorithm selection, workflow optimization, and user experience, empowering researchers to explore innovative use cases in genomics and systems biology.
Abstract: Presentation of a bioinformatics product matrix, case studies in emerging application areas, and strategies for extending multi-omics workflows across diverse research scenarios.
Bio: Dr. Yao Xiao obtained her PhD from the Hong Kong University of Science and Technology, where she applied bioinformatics tools to marine ecology studies, publishing over ten SCI-indexed papers. In early 2025, she joined MGI Tech as a Bioinformatics Product Manager and has since contributed to the development of Generative Lab Intelligence (GLI) automation solutions. Yao oversees the design and implementation of a comprehensive bioinformatics product matrix, enabling seamless integration of data processing pipelines across multi-omics applications. Her expertise spans algorithm selection, workflow optimization, and user experience, empowering researchers to explore innovative use cases in genomics and systems biology.
Dr. Shuhua Xu
Professor and Director, Center for Evolutionary Biology – Fudan University
Talk Title: “The Chinese Pangenome Reference Phase II: Building Natural Population Baselines and Advancing Medical Genetics”
Abstract: The Chinese Pangenome Consortium Phase II (CPC2) will generate high-precision long-read genomes from 500 individuals across 56 ethnic groups, integrate multi-omics platforms, develop novel functional variation annotations, and construct the highest-resolution Asian pangenome reference. As part of the Human Genome Project, CPC2 will enhance disease-susceptibility locus detection, enable precision medicine, and provide new insights into human genetic diversity evolution.
Bio: Dr. Shuhua Xu is a genomicist researching human population genetics and evolutionary biology. He leads large-scale projects that create comprehensive pangenomic references for Chinese populations, addressing underrepresented ethnic diversity in genomic studies. Xu applies advanced computational and molecular approaches to study genetic variation, adaptation, and disease mechanisms across populations. His extensive publication record in leading journals underpins his contributions to genetic resource development, improving global understanding of human diversity and personalized medicine.
Abstract: The Chinese Pangenome Consortium Phase II (CPC2) will generate high-precision long-read genomes from 500 individuals across 56 ethnic groups, integrate multi-omics platforms, develop novel functional variation annotations, and construct the highest-resolution Asian pangenome reference. As part of the Human Genome Project, CPC2 will enhance disease-susceptibility locus detection, enable precision medicine, and provide new insights into human genetic diversity evolution.
Bio: Dr. Shuhua Xu is a genomicist researching human population genetics and evolutionary biology. He leads large-scale projects that create comprehensive pangenomic references for Chinese populations, addressing underrepresented ethnic diversity in genomic studies. Xu applies advanced computational and molecular approaches to study genetic variation, adaptation, and disease mechanisms across populations. His extensive publication record in leading journals underpins his contributions to genetic resource development, improving global understanding of human diversity and personalized medicine.
Chentao Yang
Deputy Director – Institute for Digitization of Earth Life, BGI
Talk Title: “An Integrated Toolkit Advancing Cyclone Performance for Genome Research”
Abstract: Development of CycSim read simulator, CyCorrector deep-learning error-corrector, and minimap2-cyc alignment parameters to improve mapping and assembly accuracy for Cyclone nanopore data across high-complexity genomes, metagenomes, and structural-variant detection.
Bio: Chentao Yang’s expertise lies in genome assembly, bioinformatics, and deploying novel nanopore sequencing platforms, notably CycloneSEQ. He develops comprehensive software toolkits that enhance sequencing accuracy and data analysis for complex genomes, including applications in vertebrate genomics and population genetics. Yang contributes to international consortia such as the Vertebrate Genomes Project and Human Pangenome Consortium. His work supports large-scale, high-quality genome projects providing insights into evolutionary biology and disease genomics.
Abstract: Development of CycSim read simulator, CyCorrector deep-learning error-corrector, and minimap2-cyc alignment parameters to improve mapping and assembly accuracy for Cyclone nanopore data across high-complexity genomes, metagenomes, and structural-variant detection.
Bio: Chentao Yang’s expertise lies in genome assembly, bioinformatics, and deploying novel nanopore sequencing platforms, notably CycloneSEQ. He develops comprehensive software toolkits that enhance sequencing accuracy and data analysis for complex genomes, including applications in vertebrate genomics and population genetics. Yang contributes to international consortia such as the Vertebrate Genomes Project and Human Pangenome Consortium. His work supports large-scale, high-quality genome projects providing insights into evolutionary biology and disease genomics.
Meng Yang
Senior Vice President – MGI Tech
Talk Title: “AI Transforms Life Sciences: MGI’s Journey from ‘Decoding’ to ‘Designing’”
Abstract: Overview of MGI’s integration of AI and biotech in semiconductor sequencing and lab automation, highlighting technical breakthroughs, R&D experiences, standards development, and future trends in AI-enabled life science technologies.
Bio: Meng Yang oversees biotechnology innovation integrating sequencing and artificial intelligence at MGI. With leadership roles spanning R&D and corporate strategy, he advances semiconductor-based sequencing technologies and AI-powered automation systems for genomics laboratories. His work drives improvement in sequencing throughput, accuracy, and workflow efficiency. With numerous patents and contributions to national and international standards, Meng’s initiatives accelerate the transformation of sequencing platforms from decoding genomes to enabling genomic design, fostering breakthroughs in precision medicine, agriculture, and biotechnology industries worldwide.
Abstract: Overview of MGI’s integration of AI and biotech in semiconductor sequencing and lab automation, highlighting technical breakthroughs, R&D experiences, standards development, and future trends in AI-enabled life science technologies.
Bio: Meng Yang oversees biotechnology innovation integrating sequencing and artificial intelligence at MGI. With leadership roles spanning R&D and corporate strategy, he advances semiconductor-based sequencing technologies and AI-powered automation systems for genomics laboratories. His work drives improvement in sequencing throughput, accuracy, and workflow efficiency. With numerous patents and contributions to national and international standards, Meng’s initiatives accelerate the transformation of sequencing platforms from decoding genomes to enabling genomic design, fostering breakthroughs in precision medicine, agriculture, and biotechnology industries worldwide.
Dr. Yong Zhang
Principal Scientist, Bio-intelligence Institute, BGI Research Wuhan
Talk Title: “Joint Analysis of the Single-Cell and Spatial Omics Datasets”
Abstract: Development of the DCS Cloud platform’s “3+1” AI-powered framework integrating automated big-data computation, data warehousing, and interactive analysis to process hundreds of petabytes of single-cell and spatial omics data, enabling applications such as 500 nm-resolution spatial transcriptomics visualization and 3D neural reconstruction, and supporting high-throughput precision oncology and systems biology workflows.
Bio: Dr. Yong Zhang joined BGI in 2010 and leads the Bio-intelligence Institute at BGI Research Wuhan. He pioneered the DCS Cloud platform for large-scale bioinformatics, integrating automated big-data computation, data warehousing, and interactive analysis. Under his leadership, the platform has processed hundreds of petabytes of single-cell and spatial omics data, supporting applications such as 500 nm-resolution spatial transcriptomics visualization and 3D neural reconstruction. Dr. Zhang’s team also developed seqarc compression software and Stereo-seq processing tools (SAW, Stereopy), enabling high-throughput analysis of cohort and spatial omics studies. His innovations have transformed bioinformatics workflows and accelerated discoveries in precision oncology and systems biology.
Abstract: Development of the DCS Cloud platform’s “3+1” AI-powered framework integrating automated big-data computation, data warehousing, and interactive analysis to process hundreds of petabytes of single-cell and spatial omics data, enabling applications such as 500 nm-resolution spatial transcriptomics visualization and 3D neural reconstruction, and supporting high-throughput precision oncology and systems biology workflows.
Bio: Dr. Yong Zhang joined BGI in 2010 and leads the Bio-intelligence Institute at BGI Research Wuhan. He pioneered the DCS Cloud platform for large-scale bioinformatics, integrating automated big-data computation, data warehousing, and interactive analysis. Under his leadership, the platform has processed hundreds of petabytes of single-cell and spatial omics data, supporting applications such as 500 nm-resolution spatial transcriptomics visualization and 3D neural reconstruction. Dr. Zhang’s team also developed seqarc compression software and Stereo-seq processing tools (SAW, Stereopy), enabling high-throughput analysis of cohort and spatial omics studies. His innovations have transformed bioinformatics workflows and accelerated discoveries in precision oncology and systems biology.
Tiancheng (Curly) Zuo
Product Manager – GLI, BGI
Talk Title: “GLI New Product Launch”
Abstract: Overview of Generative Lab Intelligence (GLI) department organization and the capabilities of the newly launched GLI product line for multi-omics and bioinformatics solutions.
Bio: Tiancheng Zuo has experience spanning product management, marketing, and executive support within BGI, currently overseeing GLI product development and commercial activities. His role involves coordinating cross-functional teams to launch genomic instruments and maintain customer engagement, contributing to broader technology adoption. Zuo drives strategies to optimize platform performance and market positioning, supporting GLI’s growth in the genomics instrumentation sector.
Abstract: Overview of Generative Lab Intelligence (GLI) department organization and the capabilities of the newly launched GLI product line for multi-omics and bioinformatics solutions.
Bio: Tiancheng Zuo has experience spanning product management, marketing, and executive support within BGI, currently overseeing GLI product development and commercial activities. His role involves coordinating cross-functional teams to launch genomic instruments and maintain customer engagement, contributing to broader technology adoption. Zuo drives strategies to optimize platform performance and market positioning, supporting GLI’s growth in the genomics instrumentation sector.
Jack Wang
Project Lead, FluoXpert project
Abstract: Spatial proteomics has been named the “Method of the Year” by Nature Methods as it can significantly enhance the accuracy of pathological diagnosis by resolving the spatial distribution of protein biomarkers. FluoXpert enables simultaneous staining of over 20 markers on a single tissue section, providing richer cell-type information and further improving the identification accuracy of spatial distribution patterns across different cell subpopulations. Alongside STOmics technology, this platform can validate single-cell and spatial transcriptomic data, precisely locate rare cell populations in space, facilitate novel target discovery, and comprehensively reveal the composition and architecture of the tumor microenvironment.
Bio: Jack Wang holds a PhD in Oncology from the University of Alberta, Canada. He is the Project Lead for the FluoXpert project at MGI, where he leads development of multiplexed immunofluorescence and spatial proteomics platforms. His work focuses on integrating high-throughput imaging with sequencing-based detection to advance tumor microenvironment profiling and biomarker discovery. Jack has authored multiple papers in peer-reviewed journals including Nature Communications. He manages cross-functional teams, drives product roadmap and validation studies, and collaborates with academic and clinical partners to translate spatial proteomics into diagnostic and research applications. He is committed to translating spatial technologies into clinical impact.
